Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for purine and pyrimidine synthesis. This limits DNA, RNA and protein production in rapidly dividing cells, resulting in immunosuppression, anti‑inflammatory activity, and cytotoxicity against malignant cells.

The dose of Methofill is individualized and set by the prescribing clinician based on the specific indication, patient characteristics, and response to therapy. No standard dosing regimen is provided here; the prescriber determines the appropriate amount and schedule.

Methofill is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of proven teratogenic risk. It is also not recommended while breastfeeding, as methotrexate can be excreted in breast milk and may harm the infant.

To request Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Methofill (methotrexate) is a conventional synthetic DMARD with a well‑established efficacy profile, often used as first‑line therapy for rheumatoid arthritis and psoriasis. Compared with biologic agents, it is less expensive and administered subcutaneously, but may require more laboratory monitoring and carries a distinct safety profile, especially regarding hepatic and hematologic effects.

Methofill should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure proper handling.

Methofill is given as a subcutaneous injection. The prescriber or trained healthcare professional selects the injection site (typically the abdomen or thigh), cleans the area with an antiseptic, and administers the dose using a sterile needle and syringe according to standard aseptic technique.

Serious risks include severe liver toxicity (hepatitis or fibrosis), pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for signs of these complications.

Methofill is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, patients with known hypersensitivity to methotrexate or any excipients, and those receiving live vaccines. Caution is also advised for patients with existing blood disorders or uncontrolled infections.